Palo Alto Investors LP - Q1 2021 holdings

$1.76 Billion is the total value of Palo Alto Investors LP's 42 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 20.0% .

 Value Shares↓ Weighting
ABMD BuyABIOMED INC$183,344,000
+1.6%
575,233
+3.3%
10.45%
+10.4%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$166,556,000
-11.9%
2,205,750
+2.4%
9.49%
-4.2%
FOLD BuyAMICUS THERAPEUTICS INC$96,439,000
-46.9%
9,761,043
+24.1%
5.50%
-42.3%
BIIB BuyBIOGEN INC$96,010,000
+67.3%
343,200
+46.5%
5.47%
+81.9%
RVNC BuyREVANCE THERAPEUTICS INC$89,492,000
+18.1%
3,201,866
+19.8%
5.10%
+28.4%
EHTH BuyEHEALTH INC$76,975,000
+85.7%
1,058,370
+80.3%
4.39%
+101.8%
ACAD BuyACADIA PHARMACEUTICALS INC$60,317,000
-51.0%
2,337,877
+1.6%
3.44%
-46.7%
EPZM BuyEPIZYME INC$59,720,000
-18.4%
6,856,513
+1.7%
3.40%
-11.3%
KPTI BuyKARYOPHARM THERAPEUTICS INC$56,426,000
-30.8%
5,363,652
+1.8%
3.22%
-24.8%
SAGE BuySAGE THERAPEUTICS INC$44,947,000
-12.0%
600,500
+1.7%
2.56%
-4.3%
PRTA BuyPROTHENA CORP PLC$43,772,000
+115.4%
1,742,505
+3.0%
2.49%
+134.2%
CLVS BuyCLOVIS ONCOLOGY INC$31,481,000
+46.7%
4,484,411
+0.3%
1.79%
+59.5%
GRTS NewGRITSTONE ONCOLOGY INC$21,674,0002,298,382
+100.0%
1.24%
GOSS BuyGOSSAMER BIO INC$16,400,000
-2.5%
1,772,950
+1.9%
0.93%
+5.9%
PBYI BuyPUMA BIOTECHNOLOGY INC$13,540,000
-3.9%
1,392,997
+1.4%
0.77%
+4.3%
ANAB BuyANAPTYSBIO INC$9,409,000
+5.1%
436,592
+4.9%
0.54%
+14.3%
ALKS BuyALKERMES PLC$9,099,000
+202.9%
487,100
+223.4%
0.52%
+229.9%
DRNA BuyDICERNA PHARMACEUTICALS INC$8,507,000
+16.4%
332,713
+0.3%
0.48%
+26.6%
MGTA BuyMAGENTA THERAPEUTICS INC$5,118,000
+52.8%
432,300
+1.2%
0.29%
+65.9%
TVTX BuyTRAVERE THERAPEUTICS INC$4,147,000
-3.6%
166,069
+5.2%
0.24%
+4.4%
KZR BuyKEZAR LIFE SCIENCES INC$3,911,000
+36.7%
656,200
+19.7%
0.22%
+48.7%
SYRS NewSYROS PHARMACEUTICALS INC$603,00080,600
+100.0%
0.03%
NewMARINUS PHARMACEUTICALS INC$485,00031,330
+100.0%
0.03%
VIRX NewVIRACTA THERAPEUTICS INC$307,00033,212
+100.0%
0.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-05-17
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Biomarin Pharmaceuticals, Inc42Q3 202316.6%
UNITED THERAPEUTICS CORP DEL42Q3 202315.3%
INSMED INC42Q3 202314.1%
STAAR Surgical Company42Q3 202311.8%
AMICUS THERAPEUTICS INC42Q3 202312.1%
VANDA PHARMACEUTICALS INC42Q3 20235.8%
PROTHENA CORP PLC42Q3 20239.1%
CYTOKINETICS INC40Q3 20230.4%
ALIGN TECHNOLOGY INC39Q3 20232.5%
ABIOMED INC38Q3 202217.1%

View Palo Alto Investors LP's complete holdings history.

Latest significant ownerships (13-D/G)
Palo Alto Investors LP Q1 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ALIMERA SCIENCES INCSold outApril 03, 202300.0%
Epizyme, Inc.Sold outFebruary 14, 202300.0%
INSMED IncFebruary 14, 20235,871,2914.3%
Vanda Pharmaceuticals Inc.February 14, 20231,087,0641.4%
ALIMERA SCIENCES INCFebruary 14, 2022802,42311.6%
Clovis Oncology, Inc.February 14, 20223,997,8263.1%
STAAR SURGICAL COFebruary 14, 20221,140,5112.4%
Aimmune Therapeutics, Inc.Sold outFebruary 16, 202100.0%
AMAG PHARMACEUTICALS, INC.Sold outFebruary 16, 202100.0%
ALIMERA SCIENCES INCFebruary 14, 2020802,42416.2%

View Palo Alto Investors LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-04-03
42023-03-28

View Palo Alto Investors LP's complete filings history.

Compare quarters

Export Palo Alto Investors LP's holdings